您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Linifanib(ABT-869 AL-39324)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Linifanib(ABT-869 AL-39324)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Linifanib(ABT-869 AL-39324)图片
CAS NO:796967-16-3
规格:≥98%
包装与价格:
包装价格(元)
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)375.41
FormulaC21H18FN5O
CAS No.796967-16-3
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 75 mg/mL (199.8 mM)
Water:<1 mg/mL
Ethanol:<1 mg/mL
Solubility (In vivo)30% PEG400+0.5% Tween80+5% propylene glycol: 30 mg/mL
SynonymsAL39324; ABT-869; RG3635; ABT869; AL 39324; RG-3635; ABT 869; RG 3635; AL-39324

Chemical Name: N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl) urea

InChi Key: ACPCMBPQKQTAQY-UHFFFAOYSA-N

InChi Code: InChI=1S/C21H18FN5O/c1-12-5-10-16(22)18(11-12)27(21(24)28)14-8-6-13(7-9-14)15-3-2-4-17-19(15)20(23)26-25-17/h2-11H,1H3,(H2,24,28)(H3,23,25,26)

SMILES Code: O=C(N)N(C1=CC=C(C2=CC=CC3=C2C(N)=NN3)C=C1)C4=CC(C)=CC=C4F

实验参考方法
In Vitro

In vitro activity: Linifanib shows inhibitory to Kit, PDGFRβ and Flt4 with IC50 of 14 nM, 66 nM and 190 nM in kinases assay. Linifanib also inhibits ligand-induced KDR, PDGFRβ, Kit, and CSF-1R phosphorylation with IC50 of 2 nM, 2 nM, 31 nM and 10 nM at cellular level and this cellular potency could be affected by serum protein. Linifanib suppresses VEGF-stimulated HUAEC proliferation with IC50 of 0.2 nM. While Linifanib has weak activity against tumor cells which are not induced by VEGF or PDGF, except for MV4-11 leukemia cells (with constitutively active form of Flt3) with IC50 of 4 nM. Linifanib could cause a decrease in S and G2-M phases with a corresponding increase in the sub-G0-G1 apoptotic population in MV4-11 cells. Linifanib binds to the ATP-binding site of CSF-1R with Ki of 3 nM. Linifanib (10 nM) exhibits a reduced phosphorylation of Akt at Ser473 and decreased phosphorylation of GSK3βat Ser9 in Ba/F3 FLT3 ITD cell lines.


Kinase Assay: Potencies (IC50 values) are determined by assays of active kinase domains cloned and expressed in baculovirus using the FastBacbaculovirus expression system or obtained commercially. For tyrosine kinase assays, a biotinylated peptide substrate containing a single tyrosine is used with 1 mM ATP, anEu-cryptate–labeled anti-phosphotyrosine antibody (PT66), and Strepavidin-APC in a homogeneous time-resolved fluorescence assay. Serine/threonine kinases are assayed using 5 μM ATP, [33P]ATP, and a biotinylated peptide substrate with peptide capture and incorporation of 33P determined using a SA-Flashplate. Linifanib is assayed at multiple concentrations prepared by serial dilution of a DMSO stock solution of Linifanib. The concentration resulting in 50% inhibition of activity is calculated using nonlinear regression analysis of the concentration response data.


Cell Assay: Cells (HUAEC, HT-29, HT1080, A431, MDA-435, MDA-231, H526, DLD-1, 9L and MV4-11 cells) are seeded into 96-well plates at 2.5 × 103 per well and incubated with serum-free medium for 24 hours. Linifanib and VEGF (final, 10 ng/mL) are added and incubated for 72 hours in serum-free medium. For carcinoma cell lines, 3 × 103 cells/well are plated overnight in full growth medium. Linifanib is added to the cells in full growth medium and incubated for 72 hours. For leukemia cells, generally 5 × 104 per well are plated in full growth medium, Linifanib is added, and incubated for 72 hours. The effects on proliferation are determined by addition of Alamar Blue (final solution, 10%), incubation for 4 hours at 37 °C in a CO2 incubator and analysis in a fluorescence plate reader (544 nm, excitation: 590 nm, emission

In VivoLinifanib (0.3 mg/kg) results in complete inhibition of KDR phosphorylation in lung tissue. Linifanib also inhibits the edema response with ED50 of 0.5 mg/kg. Linifanib (7.5 and 15 mg/kg, bid) significantly inhibits both bFGF- and VEGF-induced angiogenesis in the cornea. Linifanib inhibits tumor growth in flank xenograft models including HT1080, H526, MX-1 and DLD-1 with ED75 from 4.5-12 mg/kg. Linifanib also shows efficacy in A431 and MV4-11 xenografts at low dose levels. Linifanib (12.5 mg/kg bid) reveals a decrease of microvasculure density in MDA-231 xenograft. Linifanib shows a Cmax and AUC24 hours with 0.4 μg/mL and 2.7 μgohour/mL in HT1080 fibrosarcoma model.
Animal modelMice bearing H526, DLD-1, MDA-231, MDA-435LM, HCT-116, H526, DLD-1, MDA-231, MDA-435LM, MV4-11 and MX-1 xenografts
Formulation & Dosage Dissolved in 2% ethanol, 5% Tween 80, 20% PEG400, 73% saline; 10 mg/kg; oral gavage
References

Mol Cancer Ther. 2006 Apr;5(4):995-1006; Mol Cancer Ther. 2006 Apr;5(4):1007-13; Mol Cancer Ther. 2011 Jun;10(6):949-59.

生物活性


Linifanib inhibits phosphorylation of FLT3, AKT, and GSK3β in Ba/F3 hFLT3 ITD mutant cell lines and IL-3 rescues phosphorylation of GSK3β. Mol Cancer Ther. 2011 Jun; 10(6): 949–959.



Linifanib prolongs survival of Ba/F3 FLT3 ITD injected mice in vivo. Mol Cancer Ther. 2011 Jun; 10(6): 949–959.


Linifanib prolongs survival of Ba/F3 FLT3 ITD injected mice in vivo. Mol Cancer Ther. 2011 Jun;10(6):949-59.